Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 566 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Alcohol administration; Placebo administration Clear all
Terminated Phase 2 Interventional Results available

Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)

NCT01074437
View directory record Official record
Conditions
Hemangioma
Interventions
Prednisolone (Corticosteroid), Propranolol, Placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 9 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Using Imaging to Assess Effects of THC on Brain Activity

NCT03655717
View directory record Official record
Conditions
Intoxication Alcohol, Intoxication THC, Intoxication Combined Alcohol THC
Interventions
Dronabinol, Ethanol, Placebo dronabinol, Placebo ethanol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 24, 2026, 2:04 AM EDT
Active, not recruiting Phase 2 Interventional

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

NCT04620759
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.

NCT03108482
View directory record Official record
Conditions
Acute Post-surgical Pain
Interventions
Co-crystal E-58425 (Tramadol/Celecoxib), Tramadol (Ultram®), Celecoxib (Celebrex®), Placebo
Drug
Lead sponsor
Esteve Pharmaceuticals, S.A.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse

NCT00585780
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Prazosin Tablet, Placebo Tablet
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 4 Interventional Results available

A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy

NCT00785512
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 79 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
26
States / cities
Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Cryosurgery and Cream Combination for Actinic Keratosis

NCT03037541
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Carac Cream, Placebo Cetaphil cream
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Not applicable Interventional Results available

PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)

NCT01586156
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Carvedilol, placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

Mifepristone Treatment of Alcohol Use Disorder

NCT02179749
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Use Disorders, Alcohol Abuse, Alcoholism
Interventions
Mifepristone 1200 mg daily, Standardized behavioral therapy, Placebo
Drug · Behavioral
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 24, 2026, 2:04 AM EDT
Terminated Phase 4 Interventional

iPACK Block With Dexamethasone For Total Knee Replacement

NCT04917055
View directory record Official record
Conditions
Knee Osteoarthritis, Acute Pain, Anesthesia, Local, Regional Anesthesia
Interventions
ropivacaine 0.25% with epinephrine and 6mg dexamethasone, Saline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Not applicable Interventional Results available

Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy

NCT01611155
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
venlafaxine, placebo, questionnaire administration, quality-of-life assessment
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 24, 2026, 2:04 AM EDT
Recruiting Phase 2 Interventional

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

NCT06349083
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Psilocybin, Inactive Placebo, Supportive therapy sessions
Drug · Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 4 Interventional Results available

Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI

NCT01750268
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Hazardous and Harmful Alcohol Use
Interventions
Medical Management Counseling, Topiramate, Placebo
Behavioral · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Not applicable Interventional Results available

Pioglitazone for the Treatment of Alcohol Use Disorder

NCT03864146
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Brief Behavioral Compliance Enhancement Treatment
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Long Beach, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 24, 2026, 2:04 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.

NCT02176642
View directory record Official record
Conditions
Urinary Urge Incontinence
Interventions
Oxybutynin extended release, Posterior Tibial Nerve Stimulation, Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

NCT02461927
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Ketamine + Naltrexone, Ketamine + Placebo, Placebo (psychoactive placebo midazolam) + Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 4 Interventional Results available

Sertraline Pharmacotherapy for Alcoholism Subtypes

NCT00368550
View directory record Official record
Conditions
Alcoholism
Interventions
Sertraline, Placebo
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Oct 24, 2026, 2:04 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

NCT07428538
View directory record Official record
Conditions
Hepatitis
Interventions
Larsucosterol, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
92
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Early Phase 1 Interventional Results available

Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder

NCT05656534
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 1Phase 2 Interventional

Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.

NCT03265808
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
allogeneic human mesenchymal stem cells (allo-hMSCs), Placebo
Drug
Lead sponsor
Ihsan M Salloum, MD, MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Harlingen, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 24, 2026, 2:04 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Addition of Clonidine to Ropivacaine in Adductor Canal Block

NCT03057015
View directory record Official record
Conditions
Postoperative Pain
Interventions
Clonidine, Placebo, Ropivacaine, Dexamethasone, Epinephrine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy

NCT03290378
View directory record Official record
Conditions
Pain Management
Interventions
Tramadol, Placebo
Drug · Other
Lead sponsor
Avenue Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Bakersfield, California • Pasadena, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 24, 2026, 2:04 AM EDT
Withdrawn Phase 2 Interventional

Oxytocin Treatment for Alcohol Use Disorders

NCT03636555
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 2 Interventional

Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD

NCT00640484
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
carmoterol (CHF 4226), placebo, salmeterol
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 24, 2026, 2:04 AM EDT